Enhanced Polyethylene Glycol-Linker-Drug Conjugates with Improved Release Profiles and Targeted Delivery

The present disclosure relates to novel polyethylene glycol-linker-drug conjugates with improved release profiles and targeted delivery, enhancing the efficacy and safety of pharmaceutical treatments.

The original patent disclosed polyethylene glycol-linker-drug conjugates, but they suffered from limitations in controlled release and targeted delivery. The present inventive concept addresses these limitations by introducing novel linker compounds, hydrophilic and lipophilic groups, and biodegradable matrices, enabling more efficient and site-specific delivery of therapeutic agents.

The enhanced polyethylene glycol-linker-drug conjugates comprise a polyethylene glycol residue, a linker compound, and a drug molecule. The linker compound is designed to include hydrophilic and lipophilic groups, which facilitate targeted delivery and controlled release of the drug molecule. Additionally, the conjugates can be dispersed within biodegradable matrices, allowing for sustained release over a predetermined period. The preparation method involves reacting the polyethylene glycol residue with the linker compound, followed by conjugation with the drug molecule and purification using chromatography methods.

The novelty of the present inventive concept lies in the introduction of hydrophilic and lipophilic groups in the linker compound, enabling targeted delivery and controlled release. The inventive step is the combination of these groups with biodegradable matrices, providing a synergistic effect on the release profile and efficacy of the therapeutic agents.

Alternative embodiments of the inventive concept may include the use of different linker compounds, such as peptide linkers cleavable by enzymes, or the incorporation of stabilizers and surfactants in the pharmaceutical composition. Variations may also include the application of click chemistry reactions for conjugate preparation or the use of different polyethylene glycol residues with varying molecular weights.

The enhanced polyethylene glycol-linker-drug conjugates have significant commercial potential in the pharmaceutical industry, particularly in the development of targeted therapies for cancer, autoimmune disorders, and other diseases. The market for these conjugates is expected to grow rapidly, driven by the increasing demand for more efficient and safer treatment options.